TransThera Sciences (Nanjing), Inc.
藥捷安康(南京)科技股份有限公司
(a joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2617)

COMPLETION OF PLACING OF NEW H SHARES UNDER THE GENERAL MANDATE

Sole Overall Coordinator and Sole Placing Agent

Reference is made to the announcement of TransThera Sciences (Nanjing), Inc. (the "**Company**") dated January 14, 2026 (the "**Announcement**") in relation to the Placing. Unless otherwise defined herein, capitalized terms used in this announcement shall have the same meanings as those defined in the Announcement.

COMPLETION OF THE PLACING

The Company is pleased to announce that all the conditions set out in the Placing Agreement had been fulfilled and Completion took place on January 20, 2026. An aggregate of 2,100,000 Placing Shares have been successfully placed by the Placing Agent at the Placing Price of HK$92.85 per Placing Share to not less than six Placees.

To the best of the knowledge, information and belief of the Directors having made all reasonable enquiries, the Placees are professional, institutional or other investors who and whose respective ultimate beneficial owners are Independent Third Parties. None of the Placees has become a substantial shareholder (as defined under the Listing Rules) of the Company immediately upon Completion.

The 2,100,000 Placing Shares represent approximately 0.70% of the number of existing issued H Shares and approximately 0.53% of the number of existing issued Shares of the Company immediately prior to Completion, and approximately 0.69% of the number of issued H Shares and approximately 0.53% of the number of issued Shares of the Company as enlarged by the allotment and issue of the Placing Shares.

USE OF PROCEEDS

The gross proceeds from the Placing amounted to approximately HK$194.99 million and the net proceeds from the Placing (after deducting the Placing commission and other relevant costs and expenses of the Placing) amounted to approximately HK$190.14 million. On such basis, the net issue price was approximately HK$90.54 per Placing Share.

The Company intends to allocate the net proceeds of the Placing (after deduction of expenses for issuance) as follows:

(i) approximately 60% of the net proceeds of the Placing, or approximately HK$114.08 million for the ongoing clinical trial of our Core Product, Tinengotinib, monotherapy for the treatment of cholangiocarcinoma (CCA) in the PRC, as well as research and development for other indications of our Core Product;

(ii) approximately 30% of the net proceeds of the Placing, or approximately HK$57.04 million for the research and development of other products, including TT-00973, TT-01488, and other molecules; and

(iii) approximately 10% of the net proceeds of the Placing, or approximately HK$19.01 million for working capital and general corporate purposes.

SHAREHOLDING STRUCTURE OF THE COMPANY UPON THE COMPLETION OF THE PLACING

The table below sets out a summary of the shareholding structure of the Company (i) immediately before the Completion; and (ii) immediately upon the Completion:

Class of Shares	Immediately before the Completion		Immediately upon the Completion	
	Number of issued Shares	Approximate percentage in the issued share capital of the Company (%)[1]	Number of issued Shares	Approximate percentage in the issued share capital of the Company (%)[1]
Unlisted Shares				
Core connected persons[2]	50,259,832	12.66%	50,259,832	12.60%
Other unlisted shareholders	44,971,128	11.33%	44,971,128	11.27%
Total number of Unlisted Shares	**95,230,960**	**23.99%**	**95,230,960**	**23.87%**
H Shares				
Core connected persons[2]	80,597,797	20.31%	80,597,797	20.20%
Placees	–	–	2,100,000	0.53%
Other H shareholders	221,068,876	55.70%	221,068,876	55.41%
Total number of H Shares	**301,666,673**	**76.01%**	**303,766,673**	**76.13%**
Total	**396,897,633**	**100.00%**	**398,997,633**	**100.00%**

Notes:

(1) The aggregate of the percentage figures in the table above may not add up to the relevant sub-total or total percentage figures shown due to rounding of the percentage figures to two decimal places.

(2) Including the 47,847,024 H Shares held by Dr. Frank WU (吳永謙) as beneficial owner, as well as his interest in Shares held by 32,750,773 H Shares and 50,259,832 Unlisted Shares through controlled corporations.

By order of the Board
TransThera Sciences (Nanjing), Inc.
(藥捷安康(南京)科技股份有限公司)
Dr. Frank Wu
Chairman and Chief Executive Officer

Hong Kong, January 20, 2026

The directors of the Company named in the application to which this announcement relates are: (i) Dr. Frank Wu and Mr. Wu Di as executive directors; (ii) Ms. Jia Zhongxin and Dr. Yi Hua as non-executive directors; and (iii) Mr. Li Shu Pai, Ms. Chui Hoi Yam and Ms. Zheng Zhelan as independent non-executive directors.